Berlin, Germany and Burlington, MA, December 6, 2011 - caprotec bioanalytics
GmbH announced today that it has initiated a research collaboration with Bayer
CropScience. Under the collaborative research agreement, caprotec will use its
proprietary CCMS (Capture Compound Mass Spectrometry) technology to profile the
interactions of one of Bayer CropScience's undisclosed new active ingredients in the
relevant biological system.
"We are very excited about the opportunity to collaborate with Bayer CropScience
applying our CCMS technology in the field of agrochemicals to discover the target
protein and the mode of action, allowing subsequent structural optimization," said Dr.
Hubert Köster, CEO of caprotec.
“CCMS permits the direct isolation of the agrochemical-specific subset of proteins from a
complex biological sample in an unbiased way. Due to the functional enrichment of the
proteins and their covalent attachment to the Capture Compounds, CCMS also identifies
low abundant and weakly interacting proteins. Direct interaction of the small molecules
to the proteins can be confirmed as well. The CCMS process is carried out in solution so
that even membrane proteins like ion channels and GPCRs from whole intact cells can be
identified. CCMS fills a crucial technological gap in the important field of functional
proteomics," continued Dr. Köster.
"We were impressed by the results of a CCMS pilot study, and are now looking forward
to a continuation of our successful collaboration with caprotec," stated Dr. Alexander
Klausener, Head of Research, Bayer CropScience,
About caprotec bioanalytics GmbH
caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in
Burlington, MA. The company focuses on the commercialization of its proprietary
Capture Compound Mass Spectrometry™ (CCMS) technology. The core of the CCMS
technology consists of small tri-functional molecules called Capture Compounds (CCs).
They enable a targeted isolation of proteins directly from complex biological samples in
solution. After isolation the captured proteins including membrane proteins are
identified by mass spectrometry. Providing a state-of-the-art platform for the isolation
and analysis of proteins from complex mixtures, the CCMS technology has enormous
potential in proteomics, drug development and the development of protein biomarkers.
The technology is protected by a broad patent portfolio. The company is supported by
an international scientific advisory board including one Nobel Laureate.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition
and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of
EUR 6.830 billion (2010), is one of the world's leading innovative crop science
companies in the areas of crop protection, non-agricultural pest control, seeds and traits.
The company offers an outstanding range of products and extensive service backup for
modern, sustainable agriculture and for non-agricultural applications. Bayer
CropScience has a global workforce of 20,700 and is represented in more than 120
countries. This and further news is available at: www.press.bayercropscience.com.
For further information concerning this press release, please contact:
caprotec bioanalytics GmhH
Tel.: +49 (0)30·6392-3990